Categorynews

Gene Therapies, Cell Therapies, and COVID-19 Vaccines Viral Vector Contract Manufacturing Outlook Report 2021: Spotlight on AstraZeneca’s COVID-19 Vaccine, Luxturna, Zolgensma, Emergent, Catalent – ResearchAndMarkets.com

May 27, 2021 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Outlook for Viral Vector Contract Manufacturing – Gene Therapies, Cell Therapies, and COVID-19 Vaccines” report has been added to ResearchAndMarkets.com’s offering.

This report examines the approvals and manufacturing outlook for three drug molecule types that all require viral vectors in their production: gene therapies, gene-modified cell therapies, and recombinant vector vaccines.

The report is critical for benchmarking the CMO industry’s capacity to manufacture these vital vaccines and drugs and forecasting future approvals.

Reasons to Buy

Detailed view of the geographic distribution of viral vector contract manufacturing facilities worldwide and the proportion belonging to dedicated CMOs and excess capacity manufacturers
Leader and disruptor companies in the viral vector space
Analysis of pipeline and marketed gene therapies, cell therapies, and recombinant vector vaccines, by geography, development stage, and clinical trials
A detailed model forecasting future gene therapy, cell therapy, and recombinant vector vaccine approvals, and associated manufacturing volumes
Contract manufacturing agreements for the active pharmaceutical ingredient (API) component of these vaccines and therapies

Key Topics Covered:

1 Executive Summary

2 Players

3 Technology Briefing

3.1 Gene Therapies

3.2 Gene-Modified Cell Therapies

3.3 Recombinant Vector Vaccines

3.4 What Are Viral Vectors?

4 Trends

5 Industry Analysis

5.1 Pipeline Therapies and Vaccines

5.2 Marketed Therapies and Vaccines

5.3 Clinical Trials

5.3.1 Gene Therapies and Gene-Modified Cell Therapies

5.3.2 Recombinant Vector Vaccines

5.4 Top Therapy Areas and Indications

5.4.1 Gene Therapies and Gene-Modified Cell Therapies

5.4.2 Recombinant Vector Vaccines

6 Approvals and Volume Model

6.1 Projected Sales

6.1.1 Spotlight on Luxturna

6.1.2 Spotlight on Zolgensma

6.1.3 Spotlight on AstraZeneca’s COVID-19 Vaccine

6.1.4 Combined Recombinant Vector Vaccines

6.2 Gene Therapy and Gene-Modified Cell Therapy Volume Model

6.2.1 Product Approval

6.2.2 Benchmark Therapies

6.2.3 Commercial Demand

6.2.4 Clinical Demand

6.3 Recombinant Vector Vaccine Volume Model

6.4 Bioreactor Capacity

7 Value Chain – Contract Manufacturing Capabilities

7.1 Viral Vector Manufacturing Sites

7.2 Company Investments in Viral Vector Manufacturing

7.3 Spotlight on Emergent

7.4 Spotlight on Catalent

7.5 Spotlight on Thermo Fisher Scientific/Patheon

7.6 Other Company Investments

7.7 Contract Manufacturing Agreements

7.8 What It Means

7.8.1 The Future of Manufacturing

7.8.2 Cell Lines and Automation

8 Companies

9 Appendix

Companies Mentioned

4D Molecular Therapeutics Inc
Abeona Therapeutics Inc
ActogeniX NV
Adaptimmune Ltd
Adrenas Therapeutics Inc Aspa Therapeutics Inc BridgeBio Pharma Inc
Advanced BioScience Laboratories Inc
Advantagene Inc
Advaxis Inc
Advent Srl
AGC Biologics SpA
Ajinomoto Bio-Pharma Services
Albany Molecular Research Inc
Albert B. Sabin Vaccine Institute Inc
Aldevron LLC
Almac Group Ltd
Altimmune Inc
Amicus Therapeutics Inc
Anchiano Therapeutics Ltd
Aruvant Sciences Inc
ASC Therapeutics Inc
Aslan Pharmaceuticals Ltd
Aspen Pharmacare Holdings Ltd
AstraZeneca
University of Oxford
Attwill Medical Solutions
Batavia Biosciences BV
Baxter Biopharma Solutions
Benitec Biopharma Inc
BioCell Corp Ltd
Biological E Ltd
BioReliance Corp
bluebird bio Inc
Boehringer Ingelheim Biopharmaceuticals GmbH Boehringer Ingelheim RCV GmbH & Co KG
BriaCell Therapeutics Corp
Caladrius Biosciences Inc
Candel Therapeutics
Catalent Inc
Cell and Gene Therapy Catapult
Cell Therapies Pty Ltd
Cellectis SA
CELLforCURE
Celsion Corp
Centaur Biopharmaceutical Services Inc
Centre C3i
Chinook Therapeutics Inc
City of Hope
Coalition for Epidemic Preparedness Innovations Public Health Vaccines LLC
Cobra Biologics Ltd
CombiGene AB
Corautus Genetics Inc. (Inactive)
CRISPR Therapeutics AG
Daiichi Sankyo Biotech Co Ltd
Decibel Therapeutics Inc
DiNAQOR AG
Dompe Farmaceutici SpA
Editas Medicine Inc
Eiger BioPharmaceuticals Inc
ElevateBio LLC
Emergent BioSolutions Inc
enGene Inc
Flexion Therapeutics Inc
Forte Biosciences Inc
Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung eV
Freeline Therapeutics Holdings Plc
Fujifilm Diosynth Biotechnologies USA Inc
Gamaleya Federal Research Center of Epidemiology and Microbiology
Genethon SA Sarepta Therapeutics Inc
Genprex Inc
Genscript Biotech Corp
GenVec LLC
GeoVax Labs Inc
German Center for Infection Research
GlaxoSmithKline Plc
Grand River Aseptic Manufacturing Inc
Halix BV
Handl Therapeutics BV
Helocyte Biosciences Inc
Helocyte, Inc.
Hookipa Pharma Inc
IDT Biologika GmbH
IN8bio Inc
Indapta Therapeutics Inc
Innobation Co Ltd
Insud Pharma
International AIDS Vaccine Initiative
Ion Channel Innovations LLC
iosBio Pharma Ltd
Iovance Biotherapeutics Inc
IVERIC bio Inc
Janssen Pharmaceutica
JCR Pharmaceuticals Co Ltd
Jenner Institute
Johnson & Johnson
Juventas Therapeutics Inc
KBI Biopharma Inc
Kite Pharma Inc
Laboratorio Reig Jofre SA
Lentigen Technology Inc
Les Laboratoires Servier SAS
Lonza Group Ltd
Lysogene SAS
Massachusetts General Hospital
MaSTherCell SA
MaxCyte Inc
Merck KGaA
MilliporeSigma
Minaris Regenerative Medicine GmbH
Minaris Regenerative Medicine LLC
Minaris Regenerative Medicine LLC Showa Denko Materials Co Ltd
MTG Biotherapeutics Inc
Mustang Bio Inc
Noga Therapeutics Ltd
Novartis
Novasep Holding SAS
Novavax Inc
Ology Bioservices Inc
OncoSec Medical Inc
Oncternal Therapeutics
Orchard Therapeutics Plc
Otsuka Holdings Co Ltd
Oxford BioMedica Plc
Oxford-Emergent Tuberculosis Consortium Limited (Inactive)
Passage Bio Inc
Patheon
Pfizer Inc
Pharmasyntez
Poseida Therapeutics Inc
Prevail Therapeutics Inc
ProBioGen AG
Profectus BioSciences Inc
Provecs Medical GmbH
PTC Therapeutics Inc
Rega Institute for Medical Research
RegenxBio Inc
ReiThera Srl
Renova Therapeutics Inc
Richter-Helm BioLogics GmbH & Co KG
Rocket Pharmaceuticals Inc
SanBio Company Limited
Sangamo Therapeutics France SAS
Sanofi
Sarepta Therapeutics Inc
Scenic Biotech BV
Selecta Biosciences Inc
Selexis SA
Sensorion SA
SGS Life Science Services
Sio Gene Therapies Inc
SK Bioscience
Spark Therapeutics Inc
Symbiosis Pharmaceutical Services Ltd
Synlogic Inc
Takara Bio Inc
Taysha Gene Therapies
TCR2 Therapeutics Inc
Themis Bioscience GmbH
T-Knife GmbH
Tonix Pharmaceuticals Holding Corp
Triumvira Immunologics Inc
TTY Biopharm Co Ltd
Ultragenyx Pharmaceutical Inc
UniQure NV
University of Oxford
Valneva SE
Vaxart Inc
VGXI Inc
Vibalogics GmbH
Vigene Biosciences Inc
ViGeneron GmbH
Vir Biotechnology Inc
Viralgen
Vivebiotech SL
Vivet Therapeutics SAS
Wacker Chemie AG
Waisman Biomanufacturing
WuXi AppTec
Xyphos Biosciences Inc
Yposkesi SAS
Zhejiang Hisun Pharmaceutical Co Ltd
ZIOPHARM Oncology Inc